



Humoral and Cellular Response after COVID-19 Vaccination

Guest Editor:

Dr. Michal Herman-Edelstein

Department of Nephrology and Hypertension, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv University, Petah Tikva, Israel

Deadline for manuscript submissions:

closed (31 December 2023)

Message from the Guest Editor

COVID-19 vaccines are effective for infection outbreak control. However, waning immunity over time and the emergence of new SARS-CoV-2 variants have caused immune resistance to current vaccines.

This Special Issue focuses on the long-term humoral and cellular responses after COVID-19 vaccination.

We are interested in manuscripts that focus on emerging issues in COVID-19 vaccination immune response as well as factors influencing current vaccines' effectiveness. Papers identifying novel strategies for improving immune response in immunocompromised patients are also of interest.

Since the long-term efficacy of COVID-19 vaccines is still unknown, we are calling for studies on both humoral and cellular long-term immunity as well as those investigating the immunity effectiveness of additional booster vaccine doses.

The submission of original articles, systematic reviews, and short communications on related topics are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com